The estimated Net Worth of Karen L. Smith is at least $2.22 Million dollars as of 5 April 2021. Karen Smith owns over 11,864 units of Acceleron Pharma Inc stock worth over $289,933 and over the last 10 years he sold XLRN stock worth over $1,663,214. In addition, he makes $271,268 as Independent Director at Acceleron Pharma Inc.
Karen has made over 6 trades of the Acceleron Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 11,864 units of XLRN stock worth $1,663,214 on 5 April 2021.
The largest trade he's ever made was selling 11,864 units of Acceleron Pharma Inc stock on 5 April 2021 worth over $1,663,214. On average, Karen trades about 579 units every 44 days since 2015. As of 5 April 2021 he still owns at least 1,622 units of Acceleron Pharma Inc stock.
You can see the complete history of Karen Smith stock trades at the bottom of the page.
Dr. Karen L. Smith M.D., Ph.D. serves as Independent Director of the Company. She has served on our Board of Directors since November 2017. Dr. Smith has over 20 years of biopharmaceutical experience bringing drugs into the clinic and through commercialization. Currently consulting internationally since January 2020, Dr. Smith previously served as President and Chief Executive Officer at Medeor Therapeutics, Inc. from May 2019 to January 2020 and Eliminate Cancer Initiative, Inc. from June 2018 to May 2019. Prior to that, Dr. Smith was Global Head of Research & Development and Chief Medical Officer at Jazz Pharmaceuticals plc from April 2015 to May 2018, where she built the R&D function into a pipeline of neuroscience and oncology products across all stages of discovery and development. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca and Bristol-Myers Squibb. Dr. Smith has also served on the boards of directors of Antares Pharma, Inc. since March 2019 and Sangamo Therapeutics, Inc. since June 2018. Previously, Dr. Smith served on the boards of directors of Forward Pharma A/S from May 2016 to May 2017 and Sucampo Pharmaceuticals, Inc. from July 2017 to February 2018. Dr. Smith holds several degrees, including an MD from the University of Warwick (UK), a PhD in Oncology from UCLA (USA)/UWA (Australia), an MBA from the University of New England, and an LLM (Masters in Law) from the University of Salford (UK). Smith’s extensive experience in global research and development and executive leadership experience at other biopharmaceutical companies qualify her to serve as a member of our Board of Directors.
As the Independent Director of Acceleron Pharma Inc, the total compensation of Karen Smith at Acceleron Pharma Inc is $271,268. There are 8 executives at Acceleron Pharma Inc getting paid more, with Habib Dable having the highest compensation of $4,273,090.
Karen Smith is 52, he's been the Independent Director of Acceleron Pharma Inc since 2018. There are 10 older and 1 younger executives at Acceleron Pharma Inc. The oldest executive at Acceleron Pharma Inc is Jay Backstrom, 65, who is the Executive Vice President - Research and Development.
Karen's mailing address filed with the SEC is 2001 MARKET STREET, SUITE 3915 UNIT #15, PHILADELPHIA, PA, 19103.
Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops, and Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron Pharma Inc executives and other stock owners filed with the SEC include: